Literature DB >> 23119106

Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume.

Priya N Werahera1, Kathryn Sullivan, Francisco G La Rosa, Fernando J Kim, M Scott Lucia, Colin O'Donnell, Rameshwar S Sidhu, Holly T Sullivan, Beth Schulte, E David Crawford.   

Abstract

In this prospective, non-randomized phase-I clinical trial, we comparatively studied the performance of six laterally-directed biopsies or the modified fan-shaped biopsies (MFSB), midline sextant biopsies (MB), and transition zone biopsies (TZB) and examine their prostate cancer (PCa) detection rates. A total of 114 patients received combinations of MFSB, MB, and TZB based on prostate gland volume: those ≤15 cc received 8 biopsies; those >15 cc but ≤ 50 cc received 14 biopsies; and those >50 cc received 20 biopsies. The mean prostate-specific antigen (PSA) level, Gleason score, and prostate volume were 8.0 ng/ml, 6.4, and 47 cc, respectively. PCa detection rate of the MB was 25% while the MFSB was 22%. The overall PCa detection rate was 33.3% with all biopsies. PCa and high-grade prostatic intraepithelial neoplasia (HG-PIN) detection rates decrease as the size of the prostate increases. PCa detection rates were 50.0% for volumes ≤19.9 cc and volumes of >50 cc had a detection rate of 25.8%. PSA levels of <3.0 had PCa detection rates of 15% which increased to 58% with PSA levels >9.0. In a multivariate analysis, only TZB was significant for PCa diagnosed by PSA (β=7.4, p<0.01). Our study showed that it is important to perform both the lateral MFSB and the MB to improve overall PCa detections rates. Thus, we recommend performing MB, MFSB, and TZB based on prostate volume, as follows: 8 biopsies for ≤15 cc; 14 for those >15 cc but ≤50 cc, and 14-20 for those >50 cc.

Entities:  

Keywords:  PSA; Prostate cancer; gleason score; prostate gland volume; transrectal core biopsies

Mesh:

Substances:

Year:  2012        PMID: 23119106      PMCID: PMC3484481     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  23 in total

1.  Prostate biopsy: how many cores are enough?

Authors:  Joseph C Presti
Journal:  Urol Oncol       Date:  2003 Mar-Apr       Impact factor: 3.498

2.  Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study.

Authors:  Joseph C Presti; Gerard J O'Dowd; M Craig Miller; Rubina Mattu; Robert W Veltri
Journal:  J Urol       Date:  2003-01       Impact factor: 7.450

3.  Origin and development of carcinoma in the prostate.

Authors:  J E McNeal
Journal:  Cancer       Date:  1969-01       Impact factor: 6.860

4.  A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy.

Authors:  R J Babaian; A Toi; K Kamoi; P Troncoso; J Sweet; R Evans; D Johnston; M Chen
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

5.  The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial.

Authors:  J C Presti; J J Chang; V Bhargava; K Shinohara
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

6.  Laterally directed biopsies detect more clinically threatening prostate cancer: computer simulated results.

Authors:  Nozomu Kawata; Gary J Miller; E David Crawford; Kathleen C Torkko; J Scott Stewart; M Scott Lucia; Heidi L Miller; Daisaku Hirano; Priya N Werahera
Journal:  Prostate       Date:  2003-10-01       Impact factor: 4.104

Review 7.  Update on prostate biopsy technique.

Authors:  Atsushi Ochiai; R Joseph Babaian
Journal:  Curr Opin Urol       Date:  2004-05       Impact factor: 2.309

8.  Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate.

Authors:  Alexandre de la Taille; Patrick Antiphon; Laurent Salomon; Maguy Cherfan; Raphael Porcher; Andras Hoznek; Fabien Saint; Dimitri Vordos; Anthony Cicco; René Yiou; Elie Serge Zafrani; Dominique Chopin; Claude Clément Abbou
Journal:  Urology       Date:  2003-06       Impact factor: 2.649

9.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

10.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.

Authors:  K K Hodge; J E McNeal; M K Terris; T A Stamey
Journal:  J Urol       Date:  1989-07       Impact factor: 7.450

View more
  11 in total

1.  Anterior tumors of the prostate: diagnosis and significance.

Authors:  Priya N Werahera; E David Crawford; Francisco G La Rosa; Kathleen C Torkko; Beth Schulte; Holly T Sullivan; Adrie van Bokhoven; M Scott Lucia; Fernando J Kim
Journal:  Can J Urol       Date:  2013-10       Impact factor: 1.344

2.  Possible clinical implications of peripheral zone changes depending on prostate size.

Authors:  Joshua M Frost; Lisa A Smith; Pranav Sharma; Werner T de Riese
Journal:  Int Urol Nephrol       Date:  2019-07-18       Impact factor: 2.370

3.  Association of benign prostatic hyperplasia (BPH) volume and prostate cancer: consecutive data from an academic institution in respect to the current scientific view.

Authors:  Shadi Khalil; Werner de Riese
Journal:  World J Urol       Date:  2017-03-17       Impact factor: 4.226

4.  Effect of rTsP53 on the M1/M2 activation of bone-marrow derived macrophage in vitro.

Authors:  Zhibin Chen; Fan Li; Wen Yang; Yanbing Liang; Hao Tang; Zhenyu Li; Jingguo Wu; Huaping Liang; Zhongfu Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

5.  Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth.

Authors:  Guillermo Lorenzo; Thomas J R Hughes; Pablo Dominguez-Frojan; Alessandro Reali; Hector Gomez
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-07       Impact factor: 11.205

6.  Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind? - The Cancer.

Authors:  Rodrigo Donalisio da Silva; Fernando J Kim
Journal:  Int Braz J Urol       Date:  2015 Jan-Feb       Impact factor: 1.541

7.  The diagnostic ability of an additional midline peripheral zone biopsy in transrectal ultrasonography-guided 12-core prostate biopsy to detect midline prostate cancer.

Authors:  Inpyeong Hwang; Sang Youn Kim; Jeong Yeon Cho; Myoung Seok Lee; Seung Hyup Kim
Journal:  Ultrasonography       Date:  2015-08-18

8.  Association of prostate volume with incidence and aggressiveness of prostate cancer.

Authors:  Shadi Al-Khalil; Christine Ibilibor; James Thomas Cammack; Werner de Riese
Journal:  Res Rep Urol       Date:  2016-10-26

9.  Histological changes of the peripheral zone in small and large prostates and possible clinical implications.

Authors:  Jonathan A Guzman; Pranav Sharma; Lisa A Smith; John D Buie; Werner T de Riese
Journal:  Res Rep Urol       Date:  2019-03-21

10.  Pixel Prostate Software as a Reliable Tool in Depicting Spatial Distribution and Determination of the Prostate Cancer Volume.

Authors:  Damir Aganovic; Benjamin Kulovac; Svjetlana Radović; Nurija Bilalović; Senad Bajramović; Amel Kešmer
Journal:  Acta Inform Med       Date:  2019-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.